期刊文献+

分化型甲状腺癌的手术范围探讨 被引量:6

Extension of dissection for differentiated thyroid cancer based on frozen-section examination
下载PDF
导出
摘要 目的探讨分化型甲状腺癌中央区肿大淋巴结快速冷冻病理检查对手术方案的指导意义。方法回顾性分析206例分化型甲状腺癌患者的临床资料,根据对中央区淋巴结快速冷冻病理的检查结果,分别对甲状腺癌患者行一侧全切+峡部切除或患侧功能性颈淋巴结清扫术。结果全组均行手术治疗,其中甲状腺乳头状癌198例(96.1%),直径<1 cm的微小乳头状癌87例(43.9%),甲状腺滤泡状癌8例(3.9%)。术后随访5年,随访率100.0%,1例在术后3年、2例在术后5年复发而再次手术,其他患者无复发。结论在分化型甲状腺癌患者的手术中,对中央区淋巴结的术中快速冷冻病理检查,可指导对甲状腺癌患者手术方式的选择,减少术后复发。 Objective To evaluate frozen-section examination of central lymph nodes for surgical modality of well- differentiated thyroid cancer. Methods Clinical data of 206 patients with well-differentiated thyroid cancer undergoing thyroidectomy were analyzed. Surgical modalities were chosen as unilateral thyroid resection plus isthmic resection or functional neck dissection according to the results of frozen-section examination of central lymph nodes. Results There were 198 cases of papillary thyroid carcinoma (96.1%), among which 87 (43.9%) with size 〈 1 cm in diameter, and 8 cases of thyroid follicular carcinoma ( 3.9% ). All patients were followed up for 5 years. Recurrence occurred in one ease after 3 y and two cases after 5 y. All of them accepted reoperation. Conclusion Frozen-section examination of central lymph nodes is of value for the selection of surgical modalities in thyroidectomy of well-differentiated thyroid cancer.
出处 《实用肿瘤杂志》 CAS 2015年第2期164-166,共3页 Journal of Practical Oncology
关键词 甲状腺肿瘤/病理学 甲状腺切除术 甲状腺肿瘤/外科学 腺癌 乳头状/病理学 腺癌 乳头状/外科学 随访研究 回顾性研究 thyroid neoplasms/pathology thyroidectomy thyroid neoplasms/surgery adenocarcinoma, papillary/pathology adenocarcinoma, papillary/surgery follow-up studies retrospective studies
  • 相关文献

参考文献9

二级参考文献28

  • 1邝耀麟,沈又琴,殷志强.甲状腺分化癌[J].普外临床,1996,11(1):47-49. 被引量:10
  • 2Chen H,Probl General Surg,1997年,114卷,1期,1页
  • 3Rosato L, Avenia N, Bemante P, et al. Complications of thyroid surgery: analysis of a m-Ulticentric study on 14,034 patients operated on in Italy over 5 years[ J]. World J Surg,2004,28 ( 3 ) : 271 - 276.
  • 4Demidchik YE, Demidchik EP, Reiners C, et al. Comprehensiveclinical assessment of 740 eases of surgically treated thyroid cancer in children of Belarus [J]. Ann Surg,2006,243(4) :525 -532.
  • 5Miller BS, Doherty GM. An examination of recently revised differentiatde thyroid can-Cer guidelines[J]. Curt Opin Oncol, 2011,23(1) :1 -6.
  • 6Zaydfudim V, Feurer ID, Griffin MR, et al. The impact of lymph node involvement on survival in patients with papillary and llicularthyroid carcinoma[J]. Suegery,2008,144(6):1070 - 1077.
  • 7Bums WR,Zeiger MA. Differentiated thyroid cancer [J]. Semin 0ncol,2010,120(9):1716 -1717.
  • 8刘永锋,张浩.我国甲状腺癌外科治疗现状[J].中国实用外科杂志,2007,27(10):763-765. 被引量:39
  • 9Tuttle RM,Ball DW,Byrd D. Thyroid carcinoma[J].J Natl Compr C anc Netw,2010.1228-1274.
  • 10D'Avanzo B,LaVecchia C,Franceschi S. History of thyroid diseases and subsequent thyroid cancer risk[J].Cancer Epidemiol Biomakers Prev,1995,(3):193-199.

共引文献130

同被引文献71

  • 1许家鹏,徐德龙,梁玉龙,王克诚.分化型甲状腺癌86例手术治疗分析[J].中国肿瘤临床与康复,2006,13(5):464-464. 被引量:7
  • 2Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide in- creasing incidence of thyroid cancer: update on epidemiol- ogy and risk factors [ J ]. J Cancer Epidemiol, 2013,2013 (7) :1 - 10.
  • 3Appetecchia M, Mequle A, et al. Serum cytokeratins de- termination in differentiated thyroid carcinoma [ J ]. Exp Clin Cancer Res,2001,20(2) :253 - 256.
  • 4Giovanella L, Ceriani L, Ghelfo A, et al. Circulating cytok- eratin 19 fragments in patients with benign nodules and carcinomas of the thyroid gland[ J]. Int J Biol Markers, 2008,23( 1 ) :54 -57.
  • 5Isice Savin S,Cveji6 D,et al,Serum Cyfra 21.1 and ga- lectin-3 protein levels in relation to immunohistochemical cytokeratin 19 and galectin-3 expression in patients with thyroid tumors[J].cer Res Clin Oncol, 2010, 136 (12) :1805 - 1812.
  • 6Makki FM, Taylor SM, Shahnavaz A, et al. Serum biomar- kers of papillary thyroid cancer [J].olaryngol Head Neck Surg,2013,42(16) :1 - 10.
  • 7Giovanella L,Treglia G,Verburg FA, et al. Serum cytok- eratin 19 fragments: a dedifferentiation marker in ad- vanced thyroid cancer [ J ]. Eur Endocrinol, 2012, 167 (6) :793 -797.
  • 8Nangia Makker P, Balan V, Raz A, et al. Regulation of tumor progression by extracellular galectin-3 [ J ]. Cancer Microenvironment ,2008,1 ( 1 ) :43 - 51.
  • 9Inohara H, Segawa T, Miyauehi A, et al. Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies[ J ]. Biochem Biophys Res Communi, 2008,376 ( 3 ) : 605 - 610.
  • 10Savin S,Cvejie D, Jankovie M, et al. Expression of ga- leetin-1 and galeetin-3 in human fetal thyroid gland[J]. Histoehem Cytoehem ,2003,51 (4) :479 - 483.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部